Group Leader Group Leader

最小化 最大化

Dr. Yang was graduated from China Medical University with Bachelor Degree in Public Health, China. In 1999, he obtained his M.D. and Ph.D. in Microbiology in Yamanashi Medical University, Japan.

Dr. Yang is the candidate of the Hundred Talents Program, Chinese Academy of Sciences(CAS);

Dr. Yang has been doing HIV/AIDS research for many years, especially on genovariation and recombination of HIV in China. Dr. Yang had conducted profound studies on HIV molecular epidemic in Yunnan Province of China and identified the 2nd generation HIV recombinant forms for the first time, which revealed the mechanism of prevalent recombinants in China and illuminated the prevalent rules of CRF08_BC. Besides, Dr. Yang successfully cloned the infectious HIV epidemic strain and analyzed its biologic characteristics. All these findings were published in journals such as “AIDS”, “J Virol”, “J AIDS”, etc; and the articles were cited for more that 150 times. Findings in Yunnan also were awarded the second prized of “2006 Yunnan Provincial Natural Scientific Award”.

Tel:86-27-87198736 86-27-87198040

Contact Us Contact Us

最小化 最大化

   Tel; +86-27-87198040 (Lab);  

   Fax: +86-27-87198736    


   Address: 25 West of Xiaohongshan,Wuchang Dist,Wuhan,Hubei,P.R.Chi

   Zip code:430071


Research Interests Research Interests

最小化 最大化

Research interests

Our interests are following points: 1) to reveal the pattern of HIV genovariation, subtype transmutation and gene evolution and to clarify the gene mutation, recombination and origin of HIVsubtype. 2)to identify the mechanism of HIV drug resistance by applying the genotype and phenotype analysis of HIV. 3) to investigate the functions and mechanisms of accessory protein Vpr and Vpu on the HIV-1 replication and pathogenesis. 4) to Investigate host innate immune mechanism on HIV and HCV infection,And the mechanisms of interaction on the co-infection ofHIV and HCV.

Recent advances and achievements Recent advances and achievements

最小化 最大化

Recent advances and achievements

We havemade a significant progress on gene evolution, viral origin and biological characteristics of HIV-1 B’ subtype, and have found a new recombinant subtype of CRF48_01B in Malaysian fishermen by collaborating with Japan and Malaysia.Recently we firstly revealed the existent of a new variant CRF01_AE-v and its potential epidemic threat. All of these findings are very important on the investigation of the epidemic and vaccine design. By cooperating with other groups, we established a very useful HIV analytical technology, The Fourth HIV-1 P24 ELISA Kit,as one of the outputs which lead an advanced level on HIV-1 detection in China.

We investigatedsome factors of TRIM family which affect HIV-1 proliferation. TRIM5α decreaseHIV-1 replication by inhibitingon NF-ΚB and MAPK signaling pathways;TRIM22 mimics TRAF6 to activate NF-kB through the interaction of TRIM22 and IKK complex;identified originally TRIM62 as a kind of E3 ubiquitin ligase. These important conclusions provide us insightful ideasonHIV-1 control and therapy.We found a new mechanism of the enhancement of Vpr on HIV-1 infection to macrophage which offers theoretical basis for eradicating latent inflectional virus. We also found that the function of Vpu fromdifferent subtype is very different, which maybe is one reason for the epidemic of HIV-1

We have successfully constructed a new kind of SHIV infectious clone based on env gene derived from the main epidemic strain of CRF08_BC in China, and a correspondent SHIV/rhesus macaque infectious model has been established initially, which will be very useful for the study on the antiviral drugand vaccine test.

In the HCV study, we found a specific miRNA which can exert considerable regulation onHCV infection by regulating thehost immune response. As virus inhibitor,EGCG extracted from tea leaf has a potential anti-HCV effect, which provided a new perspective for the therapy of HCV infection.

The significance and future study The significance and future study

最小化 最大化

The significance and future study

We will take further research on the gene evolution, viral origin and biological characteristics of HIV-1; further to investigate the mechanisms of host factorsand viral proteins, Vpr and Vpu, affecting on HIV-1 replication and the host immune response to virus. Further to perfect our SHIV infected rhesus macaque model and establish an evaluation system for HIV/AIDS vaccine and drug study. Furthermore, we will study the co-infection of HIV and HCV andtry to developthe combined treatment of them.